Dashboard
1
Poor Management Efficiency with a low ROCE of 6.40%
- The company has been able to generate a Return on Capital Employed (avg) of 6.40% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SAR 3,041 Million (Small Cap)
13.00
NA
1.51%
1.22
20.18%
1.65
Revenue and Profits:
Net Sales:
769 Million
(Quarterly Results - Sep 2025)
Net Profit:
43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.11%
0%
-22.11%
6 Months
-41.63%
0%
-41.63%
1 Year
-58.18%
0%
-58.18%
2 Years
-72.24%
0%
-72.24%
3 Years
21.92%
0%
21.92%
4 Years
2.93%
0%
2.93%
5 Years
-2.82%
0%
-2.82%
Middle East Healthcare Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.24%
EBIT Growth (5y)
24.52%
EBIT to Interest (avg)
2.16
Debt to EBITDA (avg)
5.81
Net Debt to Equity (avg)
1.14
Sales to Capital Employed (avg)
0.69
Tax Ratio
5.79%
Dividend Payout Ratio
16.32%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.40%
ROE (avg)
9.64%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
2.82
EV to EBIT
17.16
EV to EBITDA
11.17
EV to Capital Employed
1.80
EV to Sales
2.46
PEG Ratio
0.13
Dividend Yield
0.91%
ROCE (Latest)
10.47%
ROE (Latest)
22.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
769.00
732.10
5.04%
Operating Profit (PBDIT) excl Other Income
150.20
170.20
-11.75%
Interest
48.00
46.60
3.00%
Exceptional Items
6.00
2.10
185.71%
Consolidate Net Profit
43.10
66.00
-34.70%
Operating Profit Margin (Excl OI)
113.70%
158.30%
-4.46%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 5.04% vs 9.11% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -34.70% vs 21.77% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,882.80
2,653.20
8.65%
Operating Profit (PBDIT) excl Other Income
662.00
558.00
18.64%
Interest
224.80
159.80
40.68%
Exceptional Items
47.70
-30.70
255.37%
Consolidate Net Profit
283.90
20.50
1,284.88%
Operating Profit Margin (Excl OI)
154.50%
138.80%
1.57%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.65% vs 23.31% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 1,284.88% vs -71.37% in Dec 2023
About Middle East Healthcare Co. 
Middle East Healthcare Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






